Myriad Genetics (MYGN) Target Lifted at Jefferies on CMS Reimbursement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Myriad Genetics (MYGN) Jumps after Higher CMS Pricing for Integrated BRAC Analysis
April 1, 2014 6:03 PM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) is higher after-hours after disclosing new pricing from the Centers for Medicare & Medicaid Services (CMS) for the sequencing of the BRCA1 and BRCA2 genes.
The new pricing resulted in a total reimbursement amount for Myriads integrated BRACAnalysis® of... More
